A study of more than 50 tumour samples and cell lines of small-cell lung cancer (SCLC) has shown that SOX2 is amplified in approximately 27% of cancers. Several fusion transcripts were also identified, including RLF–MYCL1, although its role in SCLC is unclear. Cell proliferation was suppressed in vitro by silencing SOX2 (using short hairpin RNAs) and MYCL1, which implicates these genes in driving SCLC and suggests a plausible therapeutic strategy.
ORIGINAL RESEARCH PAPER
Rudin, C. M. et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. doi:10.1038/ng.2405
Rights and permissions
About this article
Cite this article
SOX2 is amplified in small-cell lung cancer. Nat Rev Clin Oncol 9, 608 (2012). https://doi.org/10.1038/nrclinonc.2012.170
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.170